Investigational Drug Information for PF-06649751
✉ Email this page to a colleague
What is the drug development status for PF-06649751?
PF-06649751 is an investigational drug.
There have been 14 clinical trials for PF-06649751.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 6th 2020.
The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are Pfizer, Cerevel Therapeutics, LLC, and [disabled in preview].
There are eleven US patents protecting this investigational drug and seventy-nine international patents.
Summary for PF-06649751
| US Patents | 11 |
| International Patents | 79 |
| US Patent Applications | 19 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2020-01-06) |
| Vendors | 18 |
Recent Clinical Trials for PF-06649751
| Title | Sponsor | Phase |
|---|---|---|
| Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease | Cerevel Therapeutics, LLC | Phase 1 |
| Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants | Cerevel Therapeutics, LLC | Phase 1 |
| Open-label Trial in Parkinson's Disease (PD) | Cerevel Therapeutics, LLC | Phase 3 |
Clinical Trial Summary for PF-06649751
Top disease conditions for PF-06649751
Top clinical trial sponsors for PF-06649751
US Patents for PF-06649751
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-06649751 | ⤷ Try a Trial | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
| PF-06649751 | ⤷ Try a Trial | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (New York, NY) | ⤷ Try a Trial |
| PF-06649751 | ⤷ Try a Trial | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
| PF-06649751 | ⤷ Try a Trial | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | OncoTherapy Science, Inc. (Kanagawa, JP) | ⤷ Try a Trial |
| PF-06649751 | ⤷ Try a Trial | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
| PF-06649751 | ⤷ Try a Trial | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
| PF-06649751 | ⤷ Try a Trial | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | OncoTherapy Science, Inc. (Kanagawa, JP) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-06649751
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-06649751 | Argentina | AR096748 | 2033-06-27 | ⤷ Try a Trial |
| PF-06649751 | Australia | AU2014300673 | 2033-06-27 | ⤷ Try a Trial |
| PF-06649751 | Brazil | BR112015030101 | 2033-06-27 | ⤷ Try a Trial |
| PF-06649751 | Canada | CA2916653 | 2033-06-27 | ⤷ Try a Trial |
| PF-06649751 | Chile | CL2015003735 | 2033-06-27 | ⤷ Try a Trial |
| PF-06649751 | China | CN105324376 | 2033-06-27 | ⤷ Try a Trial |
| PF-06649751 | Costa Rica | CR20150634 | 2033-06-27 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
